CYP1A2
シトクロムP450 1A2は、略称CYP1A2と呼ばれ、シトクロムP450混合機能オキシダーゼのメンバーのひとつであり、人体において生体異物の代謝に関与している。
CYP1A2の発現は、様々な栄養成分によって誘導されるとみなされている。
CYP1A2のリガンド
CYP1A2の選択的な基質、誘導剤及び阻害剤の一覧を以下の表に示す。
| 基質 | 阻害剤 | 誘導剤 |
|---|---|---|
よく言及される :
他: |
強力 :
詳細不明: |
よく言及される:
他: |
薬物相互作用
→詳細は「薬物相互作用」を参照
様々な薬剤や食品との薬物相互作用があり、薬の作用が強まったり弱まったりする事が報告されている。例えば喫煙は CYP1A2 で代謝される薬の作用を弱める。
脚注
- 1 2 3 GRCh38: Ensembl release 89: ENSG00000140505 - Ensembl, May 2017
- 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000032310 - Ensembl, May 2017
- ↑ Human PubMed Reference:
- ↑ Mouse PubMed Reference:
- ↑ Fontana R, Lown K, Paine M, Fortlage L, Santella R, Felton J, Knize M, Greenberg A, Watkins P (1999). “Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers”. Gastroenterology 117 (1): 89–98. doi:10.1016/S0016-5085(99)70554-8. PMID 10381914.
- 1 2 Mentioned both in the reference named FASS and were previously mentioned in Wikipedia. Further contributions may follow other systems
- ↑ Swedish environmental classification of pharmaceuticals Facts for prescribers (Fakta för förskrivare)
- ↑ Edwards DJ, Bernier SM (1996). “Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man”. Life Sciences 59 (13): 1025–1030. doi:10.1016/0024-3205(96)00417-1. PMID 8485024.
- ↑ 平田睦子、齋藤充生、浦野勉 ほか、日本の医薬品添付文書におけるCYPに関する情報の解析研究 Bull. Natl. Inst. Health Sci., 123, 12-18 (2005) (PDF) ,国立医薬品食品衛生研究所報告第123号第一部
- 1 2 上野雅代、前原加奈子、吉住亜紀子 ほか、「入院患者への薬剤師による禁煙支援」 『医療薬学』 2008年 34巻 9号 p.882-890, doi:10.5649/jjphcs.34.882
- ↑ インデラルで指導された意外な嗜好品とは？ 日経 DIオンライン 記事:2017年5月17日
- Meijerman I, Beijnen J, Schellens J (2006). “Herb-drug interactions in oncology: focus on mechanisms of induction”. Oncologist 11 (7): 742–52. doi:10.1634/theoncologist.11-7-742. PMID 16880233.
参考文献
- Smith G, Stubbins MJ, Harries LW, Wolf CR (1999). “Molecular genetics of the human cytochrome P450 monooxygenase superfamily.”. Xenobiotica 28 (12): 1129–65. doi:10.1080/004982598238868. PMID 9890157.
- Landi MT, Sinha R, Lang NP, Kadlubar FF (1999). “Human cytochrome P4501A2.”. IARC Sci. Publ. (148): 173–95. PMID 10493258.
- Nelson DR, Zeldin DC, Hoffman SM, et al. (2004). “Comparison of cytochrome P450 (CYP)genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants.”. Pharmacogenetics 14 (1): 1–18. doi:10.1097/00008571-200401000-00001. PMID 15128046.
- Ikeya K, Jaiswal AK, Owens RA, et al. (1990). “Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression.”. Mol. Endocrinol. 3 (9): 1399–408. PMID 2575218.
- Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF (1989). “Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines.”. Proc. Natl. Acad. Sci. U.S.A. 86 (20): 7696–700. doi:10.1073/pnas.86.20.7696. PMID 2813353.
- Quattrochi LC, Okino ST, Pendurthi UR, Tukey RH (1986). “Cloning and isolation of human cytochrome P-450 cDNAs homologous to dioxin-inducible rabbit mRNAs encoding P-450 4 and P-450 6.”. DNA 4 (5): 395–400. PMID 3000715.
- Quattrochi LC, Pendurthi UR, Okino ST, et al. (1986). “Human cytochrome P-450 4 mRNA and gene: part of a multigene family that contains Alu sequences in its mRNA.”. Proc. Natl. Acad. Sci. U.S.A. 83 (18): 6731–5. doi:10.1073/pnas.83.18.6731. PMID 3462722.
- Wrighton SA, Campanile C, Thomas PE, et al. (1986). “Identification of a human liver cytochrome P-450 homologous to the major isosafrole-inducible cytochrome P-450 in the rat.”. Mol. Pharmacol. 29 (4): 405–10. PMID 3517618.
- Jaiswal AK, Nebert DW, McBride OW, Gonzalez FJ (1988). “Human P(3)450: cDNA and complete protein sequence, repetitive Alu sequences in the 3' nontranslated region, and localization of gene to chromosome 15.”. J. Exp. Pathol. 3 (1): 1–17. PMID 3681487.
- Jaiswal AK, Nebert DW, Gonzalez FJ (1986). “Human P3(450): cDNA and complete amino acid sequence.”. Nucleic Acids Res. 14 (16): 6773–4. doi:10.1093/nar/14.16.6773. PMID 3755823.
- Eugster HP, Probst M, Würgler FE, Sengstag C (1993). “Caffeine, estradiol, and progesterone interact with human CYP1A1 and CYP1A2. Evidence from cDNA-directed expression in Saccharomyces cerevisiae.”. Drug Metab. Dispos. 21 (1): 43–9. PMID 8095225.
- Schweikl H, Taylor JA, Kitareewan S, et al. (1994). “Expression of CYP1A1 and CYP1A2 genes in human liver.”. Pharmacogenetics 3 (5): 239–49. doi:10.1097/00008571-199310000-00003. PMID 8287062.
- Yamazaki H, Inoue K, Mimura M, et al. (1996). “7-Ethoxycoumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes.”. Biochem. Pharmacol. 51 (3): 313–9. doi:10.1016/0006-2952(95)02178-7. PMID 8573198.
- Hakkola J, Raunio H, Purkunen R, et al. (1996). “Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy.”. Biochem. Pharmacol. 52 (2): 379–83. doi:10.1016/0006-2952(96)00216-X. PMID 8694864.
- Guengerich FP, Johnson WW (1998). “Kinetics of ferric cytochrome P450 reduction by NADPH-cytochrome P450 reductase: rapid reduction in the absence of substrate and variations among cytochrome P450 systems.”. Biochemistry 36 (48): 14741–50. doi:10.1021/bi9719399. PMID 9398194.
- Wacke R, Kirchner A, Prall F, et al. (1998). “Up-regulation of cytochrome P450 1A2, 2C9, and 2E1 in chronic pancreatitis.”. Pancreas 16 (4): 521–8. doi:10.1097/00006676-199805000-00011. PMID 9598815.
- Macé K, Bowman ED, Vautravers P, et al. (1998). “Characterisation of xenobiotic-metabolising enzyme expression in human bronchial mucosa and peripheral lung tissues.”. Eur. J. Cancer 34 (6): 914–20. doi:10.1016/S0959-8049(98)00034-3. PMID 9797707.
- Huang JD, Guo WC, Lai MD, et al. (1999). “Detection of a novel cytochrome P-450 1A2 polymorphism (F21L)in Chinese.”. Drug Metab. Dispos. 27 (1): 98–101. PMID 9884316.
- Tatemichi M, Nomura S, Ogura T, et al. (1999). “Mutagenic activation of environmental carcinogens by microsomes of gastric mucosa with intestinal metaplasia.”. Cancer Res. 59 (16): 3893–8. PMID 10463577.